|
| 1 |
Evaluation of P57, P53 and Ki67 Expression in Meningiomas
İlknur Küçükosmanoğlu, Meryem İlkay Eren Karanis, Yaşar Ünlü, İlker Çöven
|
|
| 2 |
Clinical Implementation of Precision Medicine in Gastric Cancer
Jaewook Jeon, Jae-Ho Cheong
|
|
| 3 |
Identification and Validation of Circulating MicroRNA Signatures for Breast Cancer Early Detection Based on Large Scale Tissue-Derived Data
Xiaokang Yu, Jinsheng Liang, Jiarui Xu, Xingsong Li, Shan Xing, Huilan Li, Wanli Liu, Dongdong Liu, Jianhua Xu, Lizhen Huang, Hongli Du
J Breast Cancer.2018;21(4):363-370. Published online 2018 December 10
DOI: http://dx.doi.org/10.4048/jbc.2018.21.e56
|
|
| 4 |
Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma
Yong-Man Kim, Shin-Wha Lee, Young-Jae Lee, Ha-Young Lee, Jong-Eun Lee, Eun-Kyung Choi
|
|
| 5 |
Early disseminated recurrence after liver resection in solitary hepatocellular carcinoma
Jong Man Kim, Nam-Joon Yi, Choon Hyuck David Kwon, Kwang-Woong Lee, Kyung-Suk Suh, Jae-Won Joh
|
|
| 6 |
CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy
Dae-Won Lee, Seock-Ah Im, Yu Jung Kim, Yaewon Yang, Jiyoung Rhee, Im Il Na, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, In Sil Choi, Do-Youn Oh, Jee Hyun Kim, Tae-You Kim, Yung-Jue Bang
Cancer Res Treat.2017;49(3):807-815. Published online 2017 January 18
DOI: http://dx.doi.org/10.4143/crt.2016.326
|
|
| 7 |
BCL2 as a Subtype-Specific Prognostic Marker for Breast Cancer
Yong Hwa Eom, Hyung Suk Kim, Ahwon Lee, Byung Joo Song, Byung Joo Chae
J Breast Cancer.2016;19(3):252-260. Published online 2016 September 23
DOI: http://dx.doi.org/10.4048/jbc.2016.19.3.252
|
|
| 8 |
The role of microRNAs in bladder cancer
Hideki Enokida, Hirofumi Yoshino, Ryosuke Matsushita, Masayuki Nakagawa
|
|
| 9 |
Clinical significance of serum CA15-3 as a prognostic parameter during follow-up periods in patients with breast cancer
Won Gong Chu, Dong Won Ryu
|
|
